statnews.com·Jun 5, 2026
RevMed's experimental pancreatic cancer drug, daraxonrasib, is available through an expanded access program, but access remains challenging for some patients. Additionally, the FDA's voucher program, initiated by former chief Marty Makary, may undergo significant changes.
The article suggests that the FDA voucher program, initially led by Marty Makary, may undergo significant changes. For professionals tracking healthtech and biotech innovations, understanding potential shifts in regulatory incentives like the FDA voucher program is crucial, as such changes can impact the approval process timelines and market access strategies for new therapeutics, especially those in emerging fields like digital health and AI-driven drug discovery.